Gilead Sciences Given “Buy” Rating at Deutsche Bank (GILD)
Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating restated by investment analysts at Deutsche Bank in a note issued to investors on Wednesday, American Banking and Market News reports. They currently have a $132.00 price objective on the stock. Deutsche Bank’s price target indicates a potential upside of 60.94% from the stock’s previous close.
In other Gilead Sciences news, EVP Kevin Young unloaded 100,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $81.44, for a total transaction of $8,144,000.00. Following the sale, the executive vice president now directly owns 216,418 shares in the company, valued at approximately $17,625,082. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of other analysts have also recently weighed in on GILD. Analysts at Summer Street reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Wednesday. Separately, analysts at Maxim Group raised their price target on shares of Gilead Sciences from $98.00 to $101.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Needham & Company raised their price target on shares of Gilead Sciences from $85.00 to $95.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $85.31.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, February 4th. The company reported $0.55 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.50 by $0.05. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter last year, the company posted $0.50 earnings per share. Gilead Sciences’s revenue was up 20.5% compared to the same quarter last year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.